Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
unfractionated heparin + low-molecular-weight heparin
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
A combination therapy using both unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) simultaneously or sequentially. This approach leverages the complementary mechanisms of these anticoagulants, with UFH primarily inhibiting thrombin (factor IIa) and LMWH having greater activity against factor Xa. The combination has demonstrated synergistic effects in enhancing anti-factor Xa activity and releasing tissue factor pathway inhibitor, providing more effective prevention of venous thrombosis than either agent alone in experimental models.
- Brand names
- InnohepHeparin
- Other names
- LMWH + UFH
02
Targets
ATIII (Antithrombin III)Coagulation Factor IXaFXIIa (Coagulation Factor XIIa)Factor XIaF10 (Factor Xa)F2 (Thrombin)
Beyond the preview
Go deeper on unfractionated heparin + low-molecular-weight heparin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on unfractionated heparin + low-molecular-weight heparin.